SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has supported the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo. The program utilizes the SSi Mantra 3.0 surgical robotic system and represents a significant step forward for cardiac care in the region. The inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This collaboration underscores the potential of robotic systems to enhance surgical precision and patient outcomes in complex cardiac procedures.
The launch of this program is important because it demonstrates the expanding global adoption of robotic surgery, particularly in emerging markets. According to a recent company video describing the program's early activity, Kings Hospital has already completed more than 25 robotic procedures in just three weeks. This rapid adoption highlights the system's usability and the growing demand for minimally invasive surgical options in Sri Lanka. The successful implementation of the program could serve as a model for other hospitals in the region, potentially accelerating the adoption of robotic surgery across South Asia.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, pointing to rising utilization of the company's installed base. These figures indicate that the company is not only expanding its footprint but also seeing increased usage of its systems, which is crucial for long-term revenue growth and market penetration.
The next major corporate milestone is regulatory expansion, with SS Innovations pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open up significant markets and further validate the technology. The success in Sri Lanka adds to the company's growing body of clinical evidence and international experience, which could support its regulatory submissions. For investors, the expansion into new geographies and the potential for regulatory approvals represent key catalysts for future growth.
For more information, see the full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
